22Rv1

22Rv1 (Prostate Cancer CDX Model)

The 22Rv1 prostate cancer cell line was derived from a human prostate carcinoma xenograft. It is widely used to study advanced prostate cancer and castration-resistant disease. 22Rv1 expresses prostate-specific antigen (PSA) and carries androgen receptor mutations and splice variants. These traits make it a clinically relevant model for therapeutic resistance research. 

Key Features: 

• Derived from a human prostate carcinoma xenograft. 

• Expresses prostate-specific antigen (PSA). 

• Contains androgen receptor mutations and splice variants. 

• Supports both androgen-dependent and resistant growth. 

Applications: 
22Rv1 is a versatile CDX model for prostate cancer drug development. It is commonly applied in studies of androgen receptor biology and resistance pathways. Researchers use it to evaluate next-generation therapeutics for castration-resistant prostate cancer. Its reproducibility makes it valuable for biomarker validation and mechanistic research.